Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. ResApp Health Limited
  6. News
  7. Summary
    RAP   AU000000RAP5

RESAPP HEALTH LIMITED

(RAP)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ResApp Health : Alodokter to launch ResAppDx in Indonesia

08/03/2021 | 08:36pm EDT

View printer-friendly version

  • Alodokter is the largest provider of telehealth services in Indonesia
  • Launched in 2014, Alodokter brings high-quality medical services to more than 30 million monthly active users by providing an integrated mobile solution for patients and doctors
  • The Alodokter platform connects more than 50,000 doctors and 1,500 hospitals and clinics with millions of Indonesian patients
  • Alodokter to integrate ResAppDx in its online consultation platform

Brisbane, Australia, 4 August 2021 - ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, has signed a software licence agreement with Indonesian-based telehealth company Alodokter, under which Alodokter will integrate ResApp's smartphone-based acute respiratory diagnostic test ResAppDx in their chat and telehealth services. Alodokter expects to launch ResAppDx on its platform prior to 1 December 2021.

The Alodokter platform connects more than 50,000 doctors and 1,500 hospitals and clinics with millions of Indonesian patients. It also provides a wide array of services around telemedicine such as offline doctor booking, insurance services, e-pharmacy and digital healthcare content.

ResAppDx is ResApp's acute respiratory diagnostic test that uses machine-learning technology to analyse signatures in cough sounds to diagnose respiratory disease using a smartphone's inbuilt microphone. It is CE Marked in Europe and TGA approved for ARTG (Australian Register of Therapeutic Goods) listing in Australia. The launch of ResAppDx on Alodokter's platform is dependent on ResApp obtaining Indonesian regulatory approval as a medical device which ResApp expects to obtain this quarter.

Nathanael Faibis, Alodokter CEO said: 'Our secret sauce has always been our deep focus on medical excellence. ResAppDx will help us to achieve medical excellence and support Alodokter to provide reliable and trustworthy medical services for all Indonesians. ResApp's technology will allow us to serve more patients in a remote, telehealth setting and effectively diagnose and treat their respiratory disease. We are very impressed with the simplicity, ease of use and accuracy of ResAppDx.'

CEO and Managing Director of ResApp, Dr Tony Keating said: 'We are excited to be partnering with Alodokter to make ResAppDx available for use by so many doctors in Indonesia and in doing so support their objective of medical excellence. We believe our ResAppDx technology will provide significant benefit for Alodokter, their clinicians and patients and improve the management of respiratory disease in Indonesia. This partnership will create value for ResApp, Alodokter and our collective shareholders and stakeholders.'

Agreement details:
Alodokter and ResApp Health have entered into a Licence Agreement ('Agreement') where ResApp licenses the ResAppDx software development kit (SDK) to Alodokter for their use in Indonesia. The Agreement is for an initial term of two years. The licence will be exclusive in Indonesia for the first twelve months of the Agreement, and non-exclusive after that period. Either party may terminate the Agreement by giving 30 days notice. The Agreement specifies pricing on a monthly subscription basis with tiered pricing based on number of tests performed per month. At this point in time, ResApp does not anticipate this agreement to have a material impact on its operating results.

###

About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

About Alodokter
Alodokter provides an end-to-end digital solution to patients using teleconsultation, doctor booking, health content, e-pharmacy and health insurance services. Alodokter provides 15,000 online medical consultations every day. At Alodokter we strive to assist our patients to find the best solution for their health care needs. Bringing new verified medical technologies to our doctors and users is one of the ways to achieve this goal. For more information, please visit https://www.alodokter.com.

Disclaimer

ResApp Health Limited published this content on 04 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 August 2021 00:35:06 UTC.


ę Publicnow 2021
All news about RESAPP HEALTH LIMITED
09/19RESAPP HEALTH : Recruits First Patients in India in COVID-19-Related Cough Sounds Study
MT
09/19RESAPP HEALTH : First patients recruited in COVID-19 clinical study in India
PU
09/14RESAPP HEALTH : Gets Regulatory Nod for R&D Rebate; Shares Fall 6%
MT
09/13RESAPP HEALTH : receives Advanced and Overseas R&D finding
PU
09/13ResApp Health Limited Receives Advanced and Overseas R&D Finding
CI
09/01RESAPP HEALTH : Secures Indonesian Regulatory Approval for Diagnostic App
MT
08/31RESAPP HEALTH : ResAppDx receives regulatory approval in Indonesia
PU
08/31ResApp Health Limited Receives Regulatory Approval in Indonesia
CI
08/26ResApp Health Limited Reports Earnings Results for the Full Year Ended June 30, 2021
CI
08/26ResApp Health Limited Auditor Raises 'Going Concern' Doubt
CI
More news
Financials
Sales 2021 0,07  0,05  0,05 
Net income 2021 -6,77 M -4,93 M -4,93 M
Net cash 2021 6,40 M 4,66 M 4,66 M
P/E ratio 2021 -4,71x
Yield 2021 -
Capitalization 65,3 M 47,6 M 47,5 M
EV / Sales 2020 -
EV / Sales 2021 413 455 192x
Nbr of Employees 500
Free-Float 84,4%
Chart RESAPP HEALTH LIMITED
Duration : Period :
ResApp Health Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESAPP HEALTH LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Managers and Directors
Tony Keating Chief Executive Officer, Executive Director & MD
Al Rey Lunar Vice President-Finance
Roger Aston Non-Executive Chairman
Christopher Ntoumenopoulos Non-Executive Director
Brian Leedman Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
RESAPP HEALTH LIMITED-10.59%48
SNAP INC.58.52%126 265
ANGI INC.4.89%6 978
GRUBHUB INC.-19.36%5 591
PERFECT WORLD CO., LTD.-46.58%4 886
CONTEXTLOGIC INC.-66.37%3 853